Design and optimization of cyclized NK1 antagonists with controlled atropisomeric properties

Tetrahedron

Volumn 60, Issue 20, 2004, Pages 4337-4347

  Albert, Jeffrey S ^a   Ohnmacht, Cyrus ^a   Bernstein, Peter R ^a   Rumsey, William L ^a,b   Aharony, David ^a   Masek, Brian B ^a,c   Dembofsky, Bruce T ^a   Koether, Gerard M ^a   Potts, William ^a   Evenden, John L ^a  

^a ASTRAZENECA   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c Optive Research Inc   (United States)

Author keywords

Atropisomer; Neurokinin; Tachykinin

Indexed keywords

2 [2 (3,4 DICHLOROPHENYL) 4 (DIETHYLAMINO)BUTYL] 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHOL[1,2 F][1,4]OXAZOCINE 7 CARBONITRILE; 2 [2 (3,4 DICHLOROPHENYL) 4 (DIMETHYLAMINO)BUTYL] 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHOL[1,2 F][1,4]OXAZOCINE 7 CARBONITRILE; 2 [2 (3,4 DICHLOROPHENYL) 4 (METHOXYAMINO)BUTYL] 4 METHYL 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHOL[1,2 F][1,4]OXAZOCINE 7 CARBONITRILE; 2 [2 (3,4 DICHLOROPHENYL) 4 (METHYLAMINO)BUTYL] 4 METHYL 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHOL[1,2 F][1,4]OXAZOCINE 7 CARBONITRILE; 2 [2 (3,4 DICHLOROPHENYL) 4 HYDROXYBUTYL] 4 METHYL 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHOL[1,2 F][1,4]OXAZOCINE 7 CARBONITRILE; 2 [2 (3,4 DICHLOROPHENYL) 4 PIPERIDIN 1 YLBUTYL] 4 METHYL 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHOL[1,2 F][1,4]OXAZOCINE 7 CARBONITRILE; 2 [4 (TERT BUTYLAMINO) 2 (3,4 DICHLOROPHENYL)BUTYL] 4 METHYL 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHOL[1,2 F][1,4]OXAZOCINE 7 CARBONITRILE; 2 [4 CHLORO 2 (3,4 DICHLOROPHENYL)BUTYL] 4 METHYL 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHO[1,2 F][1,4]OXAZOCINE 7 CARBONITRILE; 4 (7 CYANO 4 METHYL 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHO[1,2 F][1,4]OXAZOCIN 2 YL) 3 (3,4 DICHLOROPHENYL) N METHYLBUTANAMIDE; 4 (7 CYANO 4 METHYL 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHO[1,2 F][1,4]OXAZOCIN 2 YL) 3 (3,4 DICHLOROPHENYL) N,N DIMETHYLBUTANAMIDE; 4 (7 CYANO 4 METHYL 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHO[1,2 F][1,4]OXAZOCIN 2 YL) 3 (3,4 DICHLOROPHENYL)BUTANAMIDE; 4 (7 CYANO 4 METHYL 1 OXO 1,3,4,6 TETRAHYDRO 2H NAPHTHO[1,2 F][1,4]OXAZOCIN 2 YL) 3 (3,4 DICHLOROPHENYL)BUTANOIC ACID; ANXIOLYTIC AGENT; MACROGOL 400; NEUROKININ 1 RECEPTOR ANTAGONIST; SUBSTANCE P RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYCLIZATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG POTENCY; DRUG SELECTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR MECHANICS; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS;

EID: 11144354083     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tet.2004.03.054     Document Type: Article

References (27)

1. Stout S.C., Owens M.J., Nemeroff C.B. Annu. Rev. Pharmacol. Toxicol. 41:2001;877-906
2. Chahl L.A., Urban L.A. Pharmacol. Rev. Commun. 10:1999;197-203
3. Swain C., Rupniak N.M. J. Annu. Rep. Med. Chem. 34:1999;51-60
4. Gerspacher M., Von Sprecher A. Drugs Future. 24:1999;883-892
5. Gao Z., Peet N.P. Curr. Med. Chem. 6:1999;375-388
6. Sakurada T., Sakurada C., Tan-No K., Kisara K. CNS Drugs. 8:1997;436-447
7. Snider R.M., Constantine J.W., Lowe J.A. III, Longo K.P., Lebel W.S., Woody H.A., Drozda S.E., Desai M.C., Vinick F.J., Science F.J. Science. 251:1991;435-437
8. Emonds-Alt X., Proietto V., Van Broeck D., Vilain P., Advenier C., Neliat G., Le Fur G., Brellere J.C. Bioorg. Med. Chem. Lett. 3:1993;925-930
9. Albert J.S., Aharony D., Andisik D., Barthlow H., Bernstein P.R., Bialecki R.A., Dedinas R., Dembofsky B.T., Hill D., Kirkland K., Koether G.M., Kosmider B.J., Ohnmacht C., Palmer W., Potts W., Rumsey W., Shen L., Shenvi A., Sherwood S., Warwick P.J., Russell K. J. Med. Chem. 45:2002;3972-3983
10. Albert J.S., Ohnmacht C., Bernstein P.R., Rumsey W.L., Aharony D., Alelyunas Y., Russell D.J., Potts W., Sherwood S.A., Shen L., Dedinas R.F., Palmer W.E., Abbott B.M., Russell K. J. Org. Chem. 47:2004;519-529
11. Clayden J., Pink J.H. Angew. Chem., Int. Ed. 37:1998;1937-1939
12. Ahmed A., Bragg R.A., Clayden J., Lai L.W., McCarthy C., Pink J.H., Westlund N., Yasin S.A. Tetrahedron. 54:1998;13277-13294
13. Iwamura H., Mislow K. Acc. Chem. Res. 21:1988;175-182
14. Natsugari H., Ikeura Y., Kamo I., Ishimaru T., Ishichi Y., Fujishima A., Tanaka T., Kasahara F., Kawada M., Doi T. J. Med. Chem. 42:1999;3982-3993
15. Ohnmacht C.J., Albert J.S., Bernstein P.R., Rumsey W.L., Masek B.B., Dembofsky B.T., Koether G.M., Andisik D.W., Aharony D. Bioorg. Med. Chem. 12:2004;. see doi: 10.1016/j.bmc.2004.03.015
16. Anet F.A.L., Yavari I. Tetrahedron. 34:1978;2879-2886
17. Anet F.A.L., Yavari I. J. Am. Chem. Soc. 100:1978;7814-7819
18. Burkert U., Allinger N.L. Molecular mechanics. 1982;American Chemical Society, Washington, DC
19. Sandstrom J. Dynamic NMR spectroscopy. 1982;Academic, New York
20. AESOP is an in-house molecular mechanics program (Masek, B.) derived from BIGSTRN-3 (QCPE-514) Nachbar R. Jr., Mislow K. QCPE Bull. 6:1986;96
21. Bernstein P.R., Aharony D., Albert J.S., Andisik D., Barthlow H.G., Bialecki R., Davenport T., Dedinas R.F., Dembofsky B.T., Koether G., Kosmider B.J., Kirkland K., Ohnmacht C.J., Potts W., Rumsey W.L., Shen L., Shenvi A., Sherwood S., Stollman D., Russell K. Bioorg. Med. Chem. Lett. 11:2001;2769-2773
22. Rupniak N.M.J., Tattersall F.D., Williams A.R., Rycroft W., Carlson E.J., Cascieri M.A., Sadowski S., Ber E., Hale J.J., Mills S.G., MacCoss M., Seward E., Huscroft I., Owen S., Swain C.J., Hill R.G., Hargreaves R.J. Eur. J. Pharmacol. 326:1997;201-209
23. Drug exposure is expressed in terms of amount of drug (ng) per unit of brain tissue (g) 4 h following oral dosing at the indicated quantity; see Section 5
24. ENIGMA is an in-house molecular graphics program
25. Rumsey W.L., Aharony D., Bialecki R.A., Abbott B.M., Barthlow H.G., Caccese R., Ghanekar S., Lengel D., McCarthy M., Wenrich B., Undem B., Ohnmacht C., Shenvi A., Albert J.S., Brown F., Bernstein P.R., Russell K. J. Pharmacol. Exp. Ther. 298:2001;307-315
26. Manuscript in preparation
27. Bajusz S., Ronai A.Z., Szekely J.I., Graf L., Dunai-Kovacs Z., Berzetei I. FEBS Lett. 76:1977;91-92